Results 231 to 240 of about 327,717 (360)
Schematic model showing the suggested mechanism that ZA induces classical activation of macrophages by impairing mitochondrial biofunction and inhibiting mitochondrial clearance to contribute to the pathological process of BRONJ. RAPA‐loaded nanoparticles ZDPR has shown potential in alleviating BRONJ lesions as well as treating osteoporosis or ...
Hang Zhang +10 more
wiley +1 more source
Postoperative Denosumab Therapy in Aneurysmal Bone Cysts and Osteoblastomas: A Case Series and Review of Current Literature. [PDF]
Celayir A +3 more
europepmc +1 more source
Quantification of cartilage and subchondral bone cysts on knee specimens based on a spectral photon-counting computed tomography. [PDF]
Garcelon C +8 more
europepmc +1 more source
Clinical, CBCT and Histological Analysis of a Florid Cemento-Osseous Dysplasia with Co-Occurrence of Simple Bone Cyst in the Mandible: A Case Report. [PDF]
Antoine Berbéri
openalex +1 more source
A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang +17 more
wiley +1 more source
Treatment of Simple Bone Cyst by Implantation of Porous Cuboidal Hydroxy-Apatite.
Osamu Inoue +3 more
openalex +2 more sources
F13A1‐Mediated Macrophage Activation Promotes MASH Progression via the PKM2/HIF1A Pathway
In fatty liver disease, hepatocytes exposed to palmitate release S1P, which activates calcium signaling in macrophages. Elevated calcium enhances the activity of F13A1, driving PKM2 dimerization. The PKM2 dimers cause Warburg effect, translocate to the nucleus, cooperate with HIF1A, and upregulate IL1B expression, ultimately promoting classical ...
Qianrang Lu +16 more
wiley +1 more source
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu +17 more
wiley +1 more source

